BioAffinity highlights paper on new flow cytometry method

By The Science Advisory Board staff writers

August 13, 2021 -- BioAffinity Technologies is highlighting results from a research study using a flow cytometry method it has developed.

Published in the Journal of Visualized Experiments, the results show that the company's CyPath technology is an "efficient and effective" method to analyze sputum using flow cytometry, allowing for the development of diagnostic tests for lung cancer and other lung diseases, according to the company.

CyPath is a platform technology used to diagnose cancer, and the company's first product is CyPath Lung, a noninvasive test for the early detection of lung cancer that allows patients to collect their sputum sample at home.

Copyright © 2021

Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter